Synthesis of site-specific methotrexate-IgG conjugates
- 1 August 1989
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 29 (4) , 293-302
- https://doi.org/10.1007/bf00199218
Abstract
With a view to increasing drug incorporation without loss of antibody activity, tritium-labeled methotrexate (MTX) was covalently linked to a polyclonal rabbit IgG antibody against bovine serum albumin and a monoclonal mouse IgG antibody against human renal cancer (Dal K20) by a site-specific method based on hydrazone bond formation between MTX hydrazide and the aldehyde groups generated by periodate oxidation of carbohydrate moieties in IgG (which are uncommon in the antigen-binding region). These conjugates were compared with the corresponding non-site-specific MTX-IgG conjugates produced by the N-hydroxysuccinimide active-ester method with regard to synthesis, stability, retention of antibody activity, inhibition of the target enzyme dihydrofolate reductase and antitumor effect. Incorporation levels achieved with the hydrazide method were no greater than with the active-ester method, typically 6-7 mol MTX/mol IgG. Approximately the same dihydrofolate-reductase-inhibitory capacity was observed for MTX bound by either method. Hydrazide conjugates lost bound drug more rapidly than active-ester conjugateson freeezing and thawing, on incubation at 37.degree.C and 51.degree.C, and in the presence of serum or rat liver homogenates. Exposure to rat liver homogenates at 37.degree.C, pH 4.6, for 24 h led to the loss of 50%-60% of the bound drug from hydrazide conjugates compared to 20%-30% from the active ester conjugates. Bio-Gel P-2 chromatography of low-molecular-mass fractions, obtained after exposure of each of the conjugates to liver homogenates, revealed the presence of a compound that had the same elution volume and RF on thin-layer chromatography as free MTX. Enzyme-linked immunosorbent assay showed loss of antibody activity of both types of conjugates at 51.degree.C and on freezing and thawing. In a clonogenic assay, the active-ester conjugate of Dal K20 appeared to be equally effective or slightly better as a tumor inhibitor than the corresponding hydrazide conjugate. The hydrazide method may be useful in linking MTX to those monoclonal antibodies that tend to denature when subjected to the active-ester method of linkage.Keywords
This publication has 51 references indexed in Scilit:
- Inhibition of Human Renal Cancer by Methotrexate Linked to a Monoclonal AntibodyJournal of Urology, 1989
- Site‐specific linkage of methotrexate to monoclonal antibodies using an intermediate carrierInternational Journal of Cancer, 1988
- Synthesis and testing of antibody-antifolate conjugates for drug targeting.1988
- Site‐Directed Immobilization of Glycoproteins on Hydrazide‐Containing Solid SupportsBiotechnology and Applied Biochemistry, 1987
- Studies of Methotrexate-Monoclonal Antibody Conjugates for ImmunotherapyJNCI Journal of the National Cancer Institute, 1985
- Formation of methotrexate polyglutamates in rat hepatocytes.1979
- TRANSPORT AND METABOLISM OF METHOTREXATE IN NORMAL AND RESISTANT CULTURED RAT HEPATOMA-CELLS1979
- Modification of immunoglobulin G using specific reactivity of sugar moietyImmunochemistry, 1978
- Bovine liver dihydrofolate reductase. Purification and properties of the enzymeBiochemistry, 1975
- The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities.1975